A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Eli Lilly and Company
Summary
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA * Have an ECOG performance status of ≤ 1 * Must have received ≥ 1 prior line of systemic chemotherapy for advanced or metastatic disease * Participants with asymptomatic or treated CNS disease may be eligible. Exclusion Criteria: * Have known active CNS metastases and/or carcinomatous meni…
Interventions
- DrugLY3962673
Administered orally.
- DrugCetuximab
Administered intravenously.
- DrugGemcitabine
Administered intravenously.
- Drugnab-paclitaxel
Administered intravenously.
- DrugOxaliplatin
Administered intravenously.
- Drugleucovorin
Administered intravenously.
- DrugIrinotecan
Administered intravenously.
Locations (52)
- City of HopeDuarte, California
- University of California, Los Angeles (UCLA)Santa Monica, California
- Sarah Cannon Research Institute at HealthOneDenver, Colorado
- Sibley Memorial HospitalWashington D.C., District of Columbia
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research InstituteOrlando, Florida
- Emory University School of MedicineAtlanta, Georgia